MedPath

Adding Desmopressin to Tamsulosin for Treatment of BPH

Phase 4
Recruiting
Conditions
Nocturnal Polyurea in Patients With BPH
Interventions
Registration Number
NCT05945420
Lead Sponsor
Mansoura University
Brief Summary

In this study investigators will add desmopressin for treatment of patients with benign prostatic hyperplasia and nocturnal polyurea

Detailed Description

Investigators will give a group of patients tamsulosin and desmopressin and the other group will take tamsulosin and placepo and compare the outcome regarding symptoms of being prostatic hyperplasia especially nocturia and the effect on nocturnal polyurea in patients

Recruitment & Eligibility

Status
RECRUITING
Sex
Male
Target Recruitment
160
Inclusion Criteria

Men with BPH Age more than 50years Patients with nocturia (2voids per night or More) Patients with nocturnal polyurea (urine volume More than 33%of urine allover the day) IPSS more than 12 Obstructed flow curve Post voiding residual less than 150

Exclusion Criteria
  • men with BPH with : Acute urine retention Neurogenic bladder dysfunction Cardiovascular disease Hyponatremia Urethral stricture Bladder calculi Prostate cancer

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo armPlaceboThis arm will receive tamsulosin and placepo
Desmopressin armDesmopressin AcetateThis arm will receive tamsulosin and desmopressin
Primary Outcome Measures
NameTimeMethod
Change of symptoms and nocturia disappears or improveFollow up for 6 months

Investigators will compare symptoms in the pretreatment period and follow up symptoms following treatment and record the outcome

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Urology and nephrology center

🇪🇬

Mansoura, Outside U.S./Canada, Egypt

© Copyright 2025. All Rights Reserved by MedPath